Peripheral IVs are the most frequently used invasive device in hospitals and standards for care now recommend clinically indicated replacement. This simple change can lead to improved outcomes, increased efficiencies and better patient and clinician experience of care, all aligned to the ACA.

Value Based Purchasing

This pay-for-performance breakdown shows how your dollars are at stake.

<table>
<thead>
<tr>
<th>Year</th>
<th>Clinical Process of Care</th>
<th>Patient Experience</th>
<th>Clinical Care-Outcomes</th>
<th>Safety</th>
<th>Efficiency</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>20%</td>
<td>10%</td>
<td>10%</td>
<td>25%</td>
<td>25%</td>
</tr>
<tr>
<td>2016</td>
<td>30%</td>
<td>25%</td>
<td>25%</td>
<td>25%</td>
<td>20%</td>
</tr>
<tr>
<td>2017</td>
<td>30%</td>
<td>25%</td>
<td>25%</td>
<td>25%</td>
<td>25%</td>
</tr>
<tr>
<td>2018</td>
<td>25%</td>
<td>25%</td>
<td>25%</td>
<td>25%</td>
<td>25%</td>
</tr>
<tr>
<td>2019</td>
<td>20%</td>
<td>25%</td>
<td>25%</td>
<td>25%</td>
<td>25%</td>
</tr>
</tbody>
</table>

330 Million PIVs are sold each year in the U.S. How does that impact patients?

- 70% of acute patients require a short PIV catheter.
- 60% of first attempts to insert are unsuccessful.
- 58% of patients are dissatisfied with the skill of the person starting their peripheral IV.
- 27% of patients endure 3 or more sticks.

Make BIOPATCH® part of your adoption of clinically indicated replacement for PIV care. Visit www.Ethicon.com to learn more.

Benefits of clinically indicated replacement for PIV care

- Fewer Invasive Procedures
- Improved Patient Experience
- Vein Preservation
- Fewer Skin Breaches
- Reduced Material Costs
- Increased Efficiency

BIOPATCH® Point Prevalence can help you make an informed decision.

30% of CRBSIs originate from the patient’s own skin. BIOPATCH® can help protect all lines and all lives as part of PIV care.

Make an evidence-based choice for the highest likelihood of positive clinical, economic and patient satisfaction outcomes. BIOPATCH is the only IV dressing with CHG proven in multiple randomized controlled trials. Use BIOPATCH as part of a PIV bundle to help protect the insertion site.